inclusion criteria: * male or female * age ≥18 years * proven sars-cov-2 infection (confirmed by pcr from a nasopharyngeal or lower respiratory tract sample) * a score of grade 3 to 5 on the who 9-point ordinal scale * male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period. * female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met: not a woman of childbearing potential or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment phase and for at least 4 days after the last dose of study medication - capable of giving signed informed consent which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (icf) and within this protocol.

inclusion criteria: * male or female * age ≥18 years * proven sars-cov-2 infection (confirmed by pcr from a nasopharyngeal or lower respiratory tract sample) * a score of grade 3 to 5 on the who 9-point ordinal scale * male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period. * female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met: not a woman of childbearing potential or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment phase and for at least 4 days after the last dose of study medication - capable of giving signed informed consent which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (icf) and within this protocol.

inclusion criteria: - male or female - age ≥18 years - proven sars-cov-2 infection (confirmed by pcr from a nasopharyngeal or lower respiratory tract sample) - a score of grade 3 to 5 on the who 9-point ordinal scale - male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period. - female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met: not a woman of childbearing potential or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment phase and for at least 4 days after the last dose of study medication - capable of giving signed informed consent which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (icf) and within this protocol.

inclusion criteria: - male or female - age ≥18 years - proven sars-cov-2 infection (confirmed by pcr from a nasopharyngeal or lower respiratory tract sample) - a score of grade 3 to 5 on the who 9-point ordinal scale - male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period. - female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met: not a woman of childbearing potential or a woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment phase and for at least 4 days after the last dose of study medication - capable of giving signed informed consent which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (icf) and within this protocol.